進行性頭蓋内グレード1-3髄膜腫を有する成人におけるルー管内線の研究 (MOMENTUM-1)
運動量-1:進行性頭蓋内グレード1-3髄膜腫を有する成人における[177LU]ルーテイテートの多施設、無作為化、無盲検、フェーズII研究の研究
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of [177Lu]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
調査の概要
詳細な説明
Study participants will be randomized by a 2:1 ratio to receive either [177Lu]Lu-DOTATATE or standard of care therapy as deemed appropriate by the local investigator. At time of progression, participants on the standard of care arm may cross-over to the [177Lu]Lu-DOTATATE alternative treatment arm.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Sylvia C Kurz, MD,PhD
- 電話番号:203-785-5616
- メール:Sylvia.Kurz@yale.edu
研究場所
-
-
California
-
Irvine、California、アメリカ、92697
- 募集
- University of California, Irvine
-
主任研究者:
- Daniela Bota, MD, PhD
-
コンタクト:
- Manisha Dandekar
- メール:mdandeka@hs.uci.edu
-
La Jolla、California、アメリカ、92093
- 募集
- University of California San Diego - Moores Cancer Center
-
主任研究者:
- Jona Hattangadi-Gluth, MD
-
コンタクト:
- Mohammad Amjad
- メール:mtamjad@health.ucsd.edu
-
Los Angeles、California、アメリカ、90033
- 募集
- USC Keck School of Medicine
-
コンタクト:
- Christine Duran
- メール:duran_c@med.usc.edu
-
主任研究者:
- Aram Modrek, MD, PhD
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06520
- 募集
- Yale University
-
主任研究者:
- Sylvia Kurz, MD, PhD
-
コンタクト:
- Amy Rodrigues, CCRC
- 電話番号:203-260-9632
- メール:amy.rodrigues@yale.edu
-
-
Florida
-
Jacksonville、Florida、アメリカ、32207
- 募集
- Baptist MD Anderson Cancer Center
-
主任研究者:
- Michael Olson, MD PhD
-
コンタクト:
-
副調査官:
- Andre Alvarez, MD PhD
-
Miami、Florida、アメリカ、33146
- 募集
- University of Miami
-
コンタクト:
- Lily Friedman
- メール:lxf699@med.miami.edu
-
主任研究者:
- Marina Kushnirsky, MD
-
Miami、Florida、アメリカ、33176
- 募集
- Baptist Health Medical Group Oncology
-
主任研究者:
- Matthew Hall, MD
-
コンタクト:
- Nicolas Morales
- メール:nicolas.morales1@baptisthealth.net
-
Tampa、Florida、アメリカ、33543
- 募集
- Moffitt Cancer Center
-
コンタクト:
- Abdullah Abdelkawy
- メール:Abdullah.abdelkawy@Moffitt.org
-
主任研究者:
- Andre Luiz Beer Furlan, MD, PhD
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30318
- 募集
- Piedmont Healthcare
-
コンタクト:
- Jeff Whorton, BSN,RN
- メール:jeff.whorton@piedmont.org
-
主任研究者:
- Adam Nowlan, MD, MPH
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- 募集
- Indiana University
-
主任研究者:
- Kathryn Nevel, MD
-
コンタクト:
- Lauren Perrey-Moore, RN
- メール:lperry@iu.edu
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- 募集
- University of Iowa Health Care
-
コンタクト:
- Kristin West, RN, BSN
- メール:kristin-gaimari-varner@uiowa.edu
-
主任研究者:
- Kristin Plichta, MD, PhD
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Dana-Farber/Harvard Cancer Center
-
コンタクト:
- Kathryn Partridge
- メール:Kathryn_Partridge@DFCI.HARVARD.EDU
-
主任研究者:
- Gilbert Youssef, MD
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 募集
- University of Michigan Rogel Cancer Center
-
コンタクト:
- Jen Thomas
- メール:jennifkt@med.umich.edu
-
主任研究者:
- Sean Miller, MD
-
Detroit、Michigan、アメリカ、48202
- 募集
- Henry Ford Hospital
-
コンタクト:
- Jennifer Cooper
- メール:jcoope13@hfhs.org
-
主任研究者:
- Tobias Walber, MD, PhD, MPH
-
-
New York
-
New York、New York、アメリカ、10016
- 募集
- NYU Lagone Health
-
主任研究者:
- Marissa Barbaro, MD
-
コンタクト:
- Olga Garduno-Ortega
- メール:Olga.Garduno-Ortega@nyulagone.org
-
-
North Carolina
-
Durham、North Carolina、アメリカ、22708
- 募集
- Duke University Medical Center
-
主任研究者:
- Margaret Johnson, MD
-
コンタクト:
- Kelly Moulton
- メール:kelly.moulton@duke.edu
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19107
- 募集
- Thomas Jefferson University Hospital
-
主任研究者:
- Iyad Alnahhas, MD
-
コンタクト:
- Oleksandr Kolesnikov
- 電話番号:215-600-9151
- メール:ONCTrialNow@jefferson.edu
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- MD Anderson Cancer Center
-
コンタクト:
- Wathoo Chetna
- メール:cwathoo@mdanderson.org
-
主任研究者:
- Carlos Kamiya-Matsuoka, MD
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- 募集
- Medical College of Wisconsin
-
コンタクト:
- Bailee Fritz
- メール:bfritz@mcw.edu
-
主任研究者:
- Michael Straza, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
STEP 1 REGISTRATION
- Aged >= 18 years
- Histologically confirmed diagnosis of WHO grade 1-3 meningioma
- Disease progression following at least one prior surgical intervention (biopsy or resection) and at least one prior course of radiation.
- The patient is not considered a candidate for additional surgery and/or radiation or the patient has declined additional surgery and/or radiation.
- Presence of measurable contrast-enhancing disease on gadolinium-enhanced MRI brain scan defined as at least one lesion with two perpendicular diameters measuring ≥10 mm on two or more axial slices (≤ 5 mm interslice thickness, ≤ 1 mm interslice gap) per current RANO meningioma criteria
- Progression of disease determined by local radiology review per current RANO meningioma criteria, defined as:
- ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months (196 days), or
- ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months (379 days), or
- Development of a new measurable lesion
- The following scans must be available for submission for central radiology review:
- Pre-progression gadolinium-enhanced MRI brain scan no older than 12 months (379 days) that serves as a reference for evaluation of radiographic disease progression
- Progression gadolinium-enhanced MRI brain scan
STEP 2 REGISTRATION
- Progression of disease determined by central radiology review per current RANO meningioma criteria, defined as:
- ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months (196 days), or
- ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months (379 days), or
- Development of a new measurable lesion.
- [68Ga]Ga-DOTATATE uptake on PET-CT. Positive uptake is defined as uptake at least as high as liver, based on the uptake in at least one target lesion.
- Both the patient and investigator must agree that the patient will NOT receive SSTR2-targeted therapy, surgical resection, or radiation therapy until progression of disease while on study treatment.
- Patients must be willing and able to undergo regular MRI scans of the brain and [68Ga]Ga-DOTATATE PET-CT imaging during the study.
- Patients must have recovered to CTCAE grade ≤1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include alopecia, lymphopenia, sensory neuropathy ≤ grade 2, or other ≤ grade 2 not constituting a safety risk based on the investigator's judgment).
- Adequate organ and bone marrow function as defined below (within 28 days prior to step 2 registration):
- Absolute neutrophil count (ANC) ≥ 1500/mm3
- Platelet count ≥ 75,000/mm3
- Hemoglobin ≥ 8 g/dL
- Creatinine clearance (calculated by the Cockroft-Gault method) ≥40mL/min
- AST (SGOT) and ALT (SGPT) ≤ 3 x the laboratory upper limit of normal (ULN)
- Total serum bilirubin ≤ 3 x ULN (except participants with Gilbert's Syndrome, who can have a total bilirubin ≤ 5 x ULN)
- Potassium within normal limits.
Exclusion Criteria:
- Patients with a clinical diagnosis of NF2-related schwannomatosis or with a known molecular diagnosis of NF2-related schwannomatosis.
- Patients with radiation-associated meningiomas.
- Patients with known intraspinal meningiomas or meningioma metastases outside the skull/spinal column. Meningiomas invading the skull base or orbits are not excluded.
- Prior SSTR2-targeted therapy, e.g. Somatostatin LAR or short-acting Octreotide. No limit on number of prior non-SSTR2-tartgeted systemic therapies.
- Unstable neurological symptoms requiring steroids to control symptoms at a dose of >2 mg of dexamethasone (or equivalent) daily within 28 days prior to step 2 registration.
- Patients requiring immediate local therapy (e.g. surgical resection).
- Surgical procedure within the timeframes listed below, prior to step 2 registration.
- 28 days from any prior craniotomy
- 7 days from stereotactic biopsy Note: There is no limit to the number of prior surgical interventions
- Treatment within the timeframes specified below, prior to step 2 registration.
- 28 days (or 5 half-lives, whichever is longer) for cytotoxic chemotherapy, biologic agent, investigational agent or any other systemic agent prescribed for the purpose of treating meningioma
- 6 weeks from nitrosoureas Note: There is no limit to the number of prior systemically administered therapeutic agents.
- A target lesion is excluded if it has received any of the following:
- More than 2 total prior courses of radiation
- More than 1 prior course of standard fractionated external beam radiation therapy (EBRT)
- Radiation treatment to the target lesion completed <24 weeks (168 days) before Step 2 registration.
For purposes of this criterion, one course of EBRT counts as one course regardless of duration, and each course of stereotactic radiation (1-5 fractions) counts as one course. Accordingly, a target lesion may have received at most one prior course of EBRT plus one prior course of stereotactic radiation, or two prior courses of stereotactic radiation. Prior radiation history must be evaluated on a lesion-by-lesion basis, including radiation delivered before any subsequent surgical resection.
- All types of radioligand therapy at any time prior to registration. Radioligands received for diagnostic purposes are not exclusionary.
- Known hypersensitivity to somatostatin analogues or any component of the [68Ga]Ga- DOTATATE or [177Lu]Lu-DOTATATE formulations.
- Active infection requiring current use of intravenous therapy with antibiotics.
- Active cardiovascular disease: cerebral vascular accident/stroke (≤ 6 months prior to registration), myocardial infarction (≤ 6 months prior to registration), congestive heart failure (≥ NYHA class II), unstable angina pectoris, or serious cardiac arrhythmia requiring medication.
- An active malignancy ≤ 3 years. Note: Patients with a malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Pregnant and/or breastfeeding patients who are unwilling to discontinue breast feeding.
- Participants of childbearing potential must have a negative pregnancy test within 14 days of study entry.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:[177Lu]Lu-DOTATATE
Study participants receive [177Lu]Lu-DOTATATE |
The treatment regimen consists of 4 (+2 optional) administrations of [177Lu]Lu-DOTATATE. The recommended interval between infusions is 4 weeks (+ 7 days).
他の名前:
|
|
他の:Control
Study participants receive systemic Standard of Care (SOC) Therapy. Control Arm participants crossover to [177Lu]Lu-DOTATATE at progression |
Treatments will occur at the discretion and based on clinical judgement of the local and treating investigator. Systemic SOC therapy with one of the following agents: bevacizumab, everolimus, or sunitinib.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival (PFS)
時間枠:Assessed up to 4 years
|
Proportion of patients alive without disease progression per current RANO meningioma criteria |
Assessed up to 4 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression free survival at 6 months (PFS-6)
時間枠:6 months
|
Proportion of participants alive without progression at 6 months assessed per RANO meningioma criteria |
6 months
|
|
Overall Survival at 12 months (OS-12)
時間枠:12 months
|
Proportion of participants alive at 12 months |
12 months
|
|
Overall survival (OS)
時間枠:Assessed up to 4 years
|
Proportion of patients after cross-over alive without disease progression per current RANO meningioma criteria |
Assessed up to 4 years
|
|
Progression-free Survival after cross-over (PFS2)
時間枠:Assessed up to 4 years
|
Time from cross-over to disease progression per RANO meningioma criteria or death from any cause, whichever occurs first. |
Assessed up to 4 years
|
|
Disease Control Rate (DCR)
時間枠:Assessed up to 4 years
|
Proportion of patients achieving complete response, partial response, minor response or stable disease as per RANO meningioma criteria |
Assessed up to 4 years
|
|
Objective response rate (ORR)
時間枠:Assessed up to 4 years
|
Proportion of patients achieving complete or partial response as per RANO meningioma criteria. |
Assessed up to 4 years
|
|
Number of participants by highest grade treatment-emergent adverse event (TEAE):
時間枠:Assessed up to 4 years
|
Number of participants experiencing the highest grade TEAE, graded according to CTCAE version 5.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death related to adverse event). |
Assessed up to 4 years
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Sylvia C Kurz, MD, PhD、Yale University
- 主任研究者:Erik P Sulman, MD,PhD、Duke University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- RTOG 3523
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。